Search ARM

Amplo is developing AAV gene therapies that impact the neuromuscular junction and congenital myasthenic syndromes (CMS). AMP-101, Amplo’s lead asset, is late preclinical stage, driving expression of the Dok7 protein for Dok7 CMS and multiple follow on diseases of the neuromuscular junction.

Contact Amplo Biotechnology
Visit Website